Exogenous administration of actin prevents tumour growth in mice by specifically antagonizing angiogenin, a potent inducer of neovascularization. To investigate whether the angiogenin/actin system is also of importance in renal disease, we examined the effect of actin during glomerular capillary repair in anti-Thy-1.1 mesangioproliferative glomerulonephritis. Male Wistar rats were injected intravenously with actin, a control protein, i.e. albumin, or vehicle alone at 8, 16, 24, 32, 40 and 48 h after disease induction. On day 8, actin-treated rats showed significantly more microaneurysms and persistent mesangiolysis as compared to both control groups. This was associated with increased proteinuria in actin-treated rats. Moreover, actin-treated rats showed increased counts of glomerular macrophages (+40%) and polymorphonuclear leukocytes (+100%) on day 3 as well as a decrease in glomerular endothelial area on days 3 and 8. However, no difference in early glomerular endothelial as well as non-endothelial cell proliferation was noted in actin-treated rats as compared to controls. Actin treatment had no apparent influence on mesangial cell activation (i.e. de novo expression of α-smooth muscle actin) or glomerular accumulation of fibronectin or type IV collagen. Additional in vitro studies demonstrated that extracellular actin inhibits the angiogenin but not VEGF165-induced proliferation of (glomerular) endothelial cells. Moreover, actin inhibited other, yet unidentified, serum-derived angiogenic factors. In conclusion, exogenous actin impairs glomerular capillary repair in experimental mesangioproliferative glomerulonephritis possibly due to interference with angiogenic factors such as angiogenin. Our combined in vivo and in vitro observations suggest that the release of intracellular actin during mesangiolysis is an endogenous pathway by which glomerular capillary damage is augmented.

1.
Ballermann BJ: Endothelial responses to immune injury; in Neilson EG, Couser WG (eds): Immunologic Renal Disease. Philadelphia, Lippincott-Raven, 1997, pp 627–654.
2.
Kitamura H, Sugisaki Y, Yamanaka N: Endothelial regeneration during the repair process following Habu-snake venom induced glomerular injury. Virchows Arch 1995;427:195–204.
[PubMed]
3.
Iruela-Arispe L, Gordon K, Hugo C, Duijvestijn AM, Claffey KP, Reilly M, Couser WG, Alpers CE, Johnson RJ: Participation of glomerular endothelial cells in the capillary repair of glomerulonephritis. Am J Pathol 1995;147:1715–1727.
[PubMed]
4.
Shimizu A, Masuda Y, Kitamura H, Ishizaki M, Sugisaki Y, Yamanaka N: Recovery of damaged glomerular capillary network with endothelial cell apoptosis in experimental proliferative glomerulonephritis. Nephron 1998;79:206–214.
[PubMed]
5.
Shimizu A, Kitamura H, Masuda Y, Ishizaki M, Sugisaki Y, Yamanaka N: Rare glomerular capillary regeneration and subsequent capillary regression with endothelial cell apoptosis in progressive glomerulonephritis. Am J Pathol 1997;151:1231–1239.
[PubMed]
6.
Ostendorf T, Kunter U, Eitner F, Loos A, Regele H, Kerjaschki D, Janjic N, Floege J: VEGF165 mediates glomerular endothelial repair. J Clin Invest 1999;104:913–923.
[PubMed]
7.
Vallee BL, Riordan JF: Organogenesis and angiogenin. Cell Mol Life Sci 1997;53:803–815.
8.
Verselis SJ, Olson KA, Fett JW: Regulation of angiogenin expression in human HepG2 hepatoma cells by mediators of the acute-phase response. Biochem Biophys Res Commun 1999;259:178–184.
9.
Moenner M, Gusse M, Hatzi E, Badet J: The widespread expression of angiogenin in different human cells suggests a biological function not only related to angiogenesis. Eur J Biochem 1994;226:483–490.
[PubMed]
10.
Moroianu J, Fett JW, Riordan JF, Vallee BL: Actin is a surface component of calf pulmonary artery endothelial cells in culture. Proc Natl Acad Sci USA 1993;90:3815–3819.
11.
Hu GF, Strydom DJ, Fett JW, Riordan JF, Valle BL: Actin is a binding protein for angiogenin. Proc Natl Acad Sci USA 1993;90:1217–1221.
12.
Moroianu J, Riordan JF: Nuclear translocation of angiogenin in proliferating endothelial cells is essential to its angiogenic activity. Proc Natl Acad Sci USA 1994;91:1677–1681.
13.
Olson KA, Fett JW, French TC, Key ME, Valle BL: Angiogenin antagonists prevent tumor growth in vivo. Proc Natl Acad Sci USA 1995;17:442–446.
14.
Gho YS, Chae CB: Anti-angiogenin activity of the peptides complementary to the receptor-binding site of angiogenin. J Biol Chem 1997;272:24294–24299.
15.
Gho YS, Lee JE, Oh KS, Bae DG, Chae CB: Development of anti-angiogenin peptide using a phage-displayed peptide library. Cancer Res 1997;57:3733–3740.
16.
Hu GF, Riordan JF: Angiogenin enhances actin acceleration of plasminogen activation. Biochem Biophys Res Commun 1993;197:682–687.
17.
Hu G, Riordan JF, Vallee BL: Angiogenin promotes invasiveness of cultured endothelial cells by stimulation of cell-associated proteolytic activities. Proc Natl Acad Sci USA 1994;91:12096–12100.
18.
Jimi S, Ito K, Kohno K, Ono M, Kuwano M, Itagaki Y, Ishikawa H: Modulation by bovine angiogenin of tubular morphogenesis and expression of plasminogen activator in bovine endothelial cells. Biochem Biophys Res Commun 1995;211:476–483.
19.
Johnson RJ, Iida H, Alpers CE, Majesky MW, Schwartz SM, Pritzi P, Gordon K, Gown AM: Expression of smooth muscle cell phenotype by rat mesangial cells in immune complex nephritis. α-Smooth muscle actin is a marker of mesangial cell proliferation. J Clin Invest 1991;87:847–858.
[PubMed]
20.
Alpers CE, Hudkins KL, Gown AM, Johnson RJ: Enhanced expression of ‘muscle-specific’ actin in glomerulonephritis. Kidney Int 1992;41:1134–1142.
[PubMed]
21.
Morita T, Yamamoto T, Churg J: Mesangiolysis: An update. Am J Kidney Dis 1998;31:559–573.
[PubMed]
22.
Chaponnier C, Goethals M, Janmey PA, Gabbiani F, Gabbiani G, Vanderkerckhove J: The specific NH2-terminal sequence Ac-EEED of α-smooth muscle actin plays a role in polymerization in vitro and in vivo. J Cell Biol 1995;130:887–895.
[PubMed]
23.
Floege J, Ostendorf T, Janssen U, Burg M, Radeke HH, Vargeese C, Gill SC, Green LS, Janjic N: Novel approach to specific growth factor inhibition in vivo: Antagonism of platelet-derived growth factor by aptamers. Am J Pathol 1999;154:169–179.
[PubMed]
24.
Johnson RJ, Garcia RL, Pritzl P, Alpers CE: Platelets mediate glomerular cell proliferation in immune complex nephritis induced by anti-mesangial cell antibodies in the rat. Am J Pathol 1990;136:369–374.
[PubMed]
25.
Baker AJ, Mooney A, Hughes J, Lombardi D, Johnson RJ, Savill J: Mesangial cell apoptosis: The major mechanism for resolution of glomerular hypercellularity in experimental mesangial proliferative nephritis. J Clin Invest 1994;94:2105–2116.
[PubMed]
26.
Burg M, Ostendorf T, Mooney A, Koch KM, Floege J: Treatment of experimental mesangioproliferative glomerulonephritis with non-anti-coagulant heparin: Therapeutic efficacy and safety. Lab Invest 1997;76:505–516.
[PubMed]
27.
Yoshimura A, Gordon K, Alpers CE, Floege J, Pritzl P, Ross R, Couser WG, Bowen-Pope DF, Johnson RJ: Demonstration of PDGF B-chain mRNA in glomeruli in mesangial proliferative nephritis by in situ hybridization. Kidney Int 1991;40:470–476.
[PubMed]
28.
Kim YG, Suga SI, Kang DH, Jefferson JA, Mazzali M, Gordon KL, Matsui K, Breiteneder-Geleff S, Shankland SJ, Hughes J, Kerjaschki D, Schreiner GF, Johnson RJ: Vascular endothelial growth factor accelerates renal recovery in experimental thrombotic microangiopathy. Kidney Int 2000;58:2390–2399.
[PubMed]
29.
Kliem V, Johnson RJ, Alpers CE, Yoshimura A, Couser WG, Koch KM, Floege J: Mechanisms involved in the pathogenesis of tubulointerstitial fibrosis in 5/6 nephrectomized rats. Kidney Int 1996;49:666–678.
[PubMed]
30.
Hugo C, Pichler R, Gordon K, Schmidt R, Amieva M, Couser WG, Furthmayr H, Johnson RJ: The cytoskeletal linking proteins, moesin and radixin, are upregulated by platelet-derived growth factor, but not basic fibroblast growth factor in experimental mesangial proliferative glomerulonephritis. J Clin Invest 1996;97:2499–2508.
31.
Wolf G, Ziyadeh FN, Zahner G, Stahl RAK: Angiotensin II is mitogenic for cultured rat glomerular endothelial cells. Hypertension 1996;27:897–905.
[PubMed]
32.
Heyl W, Handt S, Reister F, Gehlen J, Mittermayer C, Rath W: The role of soluble adhesion molecules in evaluating endothelial cell activation in preeclampsia. Am J Obstet Gynecol 1999;180:68–72.
33.
Iida H, Seifert R, Alpers CE, Gronwald RG, Phillips PE, Pritzl P, Gordon K, Gown AM, Ross R, Bowen-Pope DF, Johnson RJ: Platelet-derived growth factor (PDGF) and PDGF receptor are induced in mesangial proliferative nephritis in the rat. Proc Natl Acad Sci USA 1991;88:6560–6564.
[PubMed]
34.
Floege J, Johnson RJ, Gordon K, Iida H, Pritzl P, Yoshimura A, Campbell C, Alpers CE, Couser WG: Increased synthesis of extracellular matrix in mesangial proliferative glomerulonephritis. Kidney Int 1991;40:477–488.
[PubMed]
35.
Floege J, Burg M, Hugo C, Gordon KL, Van Goor H, Reidy M, Couser WG, Koch KM, Johnson RJ: Endogenous fibroblast growth factor-2 mediates cytotoxicity in experimental mesangioproliferative glomerulonephritis. J Am Soc Nephrol 1998;9:792–801.
36.
Tschesche H, Kopp C, Horl WH, Hempelmann U: Inhibition of degranulation of polymorphonuclear leukocytes by angiogenin and its tryptic fragment. J Biol Chem 1994;269:30274–30280.
37.
Cohen G, Haag-Weber M, Horl WH: Immune dysfunction in uremia. Kidney Int Suppl 1997;62:S79–S82.
You do not currently have access to this content.